Sweeteners discussed include stevia, monk fruit, and other high-intensity sweeteners
These secondary mechanisms operate in addition to not instead of the primary VEGFR2 and NO pathways
Efficacy and safety of LY3298176 (Tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial)
Dasmahapatra, University of Mississippi, United States Reviewed by Sarah Scalercio, Instituto de Cincia e Tecnologia em Biomodelos (ICTB), Brazil Wen-Xiang Liu, Capital Medical University, China Updates Copyright 2025 Jiang, Han, Qiao and Ren
The primary outcome was to compare change in HbA 1C concentration (%) and weight (kg) from baseline to 26 weeks (6 weeks) between patients receiving oral versus injectable semaglutide, stratified according to highest dose received
R.FreiR.RoduitC.ConstanciasF.Neuzil-BunesovaV.et al